Literature DB >> 19309746

Lymph node ratio predicts disease-specific survival in melanoma patients.

Yan Xing1, Brian D Badgwell, Merrick I Ross, Jeffrey E Gershenwald, Jeffrey E Lee, Paul F Mansfield, Anthony Lucci, Janice N Cormier.   

Abstract

BACKGROUND: The objectives of this analysis were to compare various measures associated with lymph node (LN) dissection and to identify threshold values associated with disease-specific survival (DSS) outcomes in patients with melanoma.
METHODS: Patients with lymph node-positive melanoma who underwent therapeutic LN dissection of the neck, axilla, and inguinal region were identified from the SEER database (1988-2005). We performed Cox multivariate analyses to determine the impact of the total number of LNs removed, number of negative LNs removed, and LN ratio on DSS. Multivariate cut-point analyses were conducted for each anatomic region to identify the threshold values associated with the largest improvement in DSS.
RESULTS: The LN ratio was significantly associated with DSS for all LN regions. The LN ratio thresholds resulting in the greatest difference in 5-year DSS were .07, .13, and .18 for neck, axillary, and inguinal regions, respectively, corresponding to 15, 8, and 6 LNs removed per positive lymph node. After adjustment for other clinicopathologic factors, the hazard ratios (HRs) were .53 (95% confidence interval [CI], .40 to .71) in the neck, .52 (95% CI, .42 to .65) in the axillary, and .47 (95% CI, .36 to .61) in the inguinal regions for patients who met the LN ratio threshold.
CONCLUSIONS: Among the prognostic factors examined, LN ratio was the best indicator of the extent of LN dissection, regardless of anatomic nodal region. These data provide evidence-based guidelines for defining adequate LN dissections in melanoma patients. (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19309746      PMCID: PMC2755291          DOI: 10.1002/cncr.24290

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

Review 1.  Management of metastatic melanoma 2005.

Authors:  Steven O'Day; Peter Boasberg
Journal:  Surg Oncol Clin N Am       Date:  2006-04       Impact factor: 3.495

2.  The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma.

Authors:  C Galliot-Repkat; R Cailliod; O Trost; A Danino; E Collet; D Lambert; P Vabres; S Dalac
Journal:  Eur J Surg Oncol       Date:  2006-07-05       Impact factor: 4.424

3.  Current surgical management of melanoma.

Authors:  Adam I Riker; Lisa Kirksey; Lee Thompson; Amy Morris; C Wayne Cruse
Journal:  Expert Rev Anticancer Ther       Date:  2006-11       Impact factor: 4.512

4.  Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?

Authors:  Theresa M Koppie; Andrew J Vickers; Kinjal Vora; Guido Dalbagni; Bernard H Bochner
Journal:  Cancer       Date:  2006-11-15       Impact factor: 6.860

5.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 6.  Lymph node evaluation and survival after curative resection of colon cancer: systematic review.

Authors:  George J Chang; Miguel A Rodriguez-Bigas; John M Skibber; Virginia A Moyer
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

7.  Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?

Authors:  Elfriede Bollschweiler; Stephan E Baldus; Wolfgang Schröder; Paul M Schneider; Arnulf H Hölscher
Journal:  J Surg Oncol       Date:  2006-10-01       Impact factor: 3.454

8.  Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database.

Authors:  Roderich E Schwarz; David D Smith
Journal:  Ann Surg Oncol       Date:  2006-09-06       Impact factor: 5.344

9.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

10.  Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer.

Authors:  Natalie G Coburn; Carol J Swallow; Alex Kiss; Calvin Law
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

View more
  11 in total

1.  Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial.

Authors:  James W Jakub; Alicia M Terando; Amod Sarnaik; Charlotte E Ariyan; Mark B Faries; Sabino Zani; Heather B Neuman; Nabil Wasif; Jeffrey M Farma; Bruce J Averbook; Karl Y Bilimoria; Travis E Grotz; Jacob B Jake Allred; Vera J Suman; Mary Sue Brady; Douglas Tyler; Jeffrey D Wayne; Heidi Nelson
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

2.  Inguinopelvic lymphadenectomy following positive inguinal sentinel lymph node biopsy in melanoma: true frequency of synchronous pelvic metastases.

Authors:  Carrie K Chu; Keith A Delman; Grant W Carlson; Andrea C Hestley; Douglas R Murray
Journal:  Ann Surg Oncol       Date:  2011-05-04       Impact factor: 5.344

3.  N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma.

Authors:  Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer
Journal:  J Gastrointest Surg       Date:  2012-12-11       Impact factor: 3.452

4.  The impact of the lymph node ratio is greater than traditional lymph node status in stage III colorectal cancer patients.

Authors:  Yen-Jung Lu; Pei-Ching Lin; Chun-Chi Lin; Huann-Sheng Wang; Shung-Haur Yang; Jeng-Kai Jiang; Yuan-Tzu Lan; Tzu-Chen Lin; Wen-Yi Liang; Wei-Shone Chen; Jen-Kou Lin; Shih-Ching Chang
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

5.  Significance of lymph node ratio on survival of women with borderline ovarian tumors.

Authors:  David J Nusbaum; Rachel S Mandelbaum; Hiroko Machida; Shinya Matsuzaki; Lynda D Roman; Anil K Sood; David M Gershenson; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2020-04-17       Impact factor: 2.344

6.  Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection.

Authors:  A P T van der Ploeg; A C J van Akkooi; P I M Schmitz; A N van Geel; J H de Wilt; A M M Eggermont; C Verhoef
Journal:  Ann Surg Oncol       Date:  2011-05-03       Impact factor: 5.344

7.  Interval sentinel lymph nodes: an unusual localization in patients with cutaneous melanoma.

Authors:  A M Manganoni; R Farfaglia; E Sereni; C Farisoglio; C Pizzocaro; D Marocolo; F Gavazzoni; L Pavoni; P Calzavara-Pinton
Journal:  Dermatol Res Pract       Date:  2011-05-04

Review 8.  Clinical Implications of Lymph Node Metastasis in Colorectal Cancer: Current Status and Future Perspectives.

Authors:  Hye Jin Kim; Gyu-Seog Choi
Journal:  Ann Coloproctol       Date:  2019-06-30

9.  Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?

Authors:  K P Wevers; E Bastiaannet; H P A M Poos; R J van Ginkel; J T Plukker; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2012-05-17       Impact factor: 5.344

10.  Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors.

Authors:  Nicola Mozzillo; Corrado Caracò; Ugo Marone; Gianluca Di Monta; Anna Crispo; Gerardo Botti; Maurizio Montella; Paolo Antonio Ascierto
Journal:  World J Surg Oncol       Date:  2013-02-04       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.